Theodore J Brown

List of Publications by Year
in descending order

118 papers	6,680 citations	71061 41 h-index	64755 79 g-index
120 all docs	120 docs citations	120 times ranked	7163 citing authors

#	Article	IF	Citations
1	Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis. Gynecologic Oncology, 2022, 164, 212-220.	0.6	9
2	Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma. Journal of Ovarian Research, 2022, 15, 50.	1.3	3
3	Cargo small non-coding RNAs of extracellular vesicles isolated from uterine fluid associate with endometrial receptivity and implantation success. Fertility and Sterility, 2021, 115, 1327-1336.	0.5	33
4	Endometrial laminin subunit beta-3 expression associates with reproductive outcome in patients with repeated implantation failure. Journal of Assisted Reproduction and Genetics, 2021, 38, 1835-1842.	1.2	3
5	A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin. Journal of Ovarian Research, 2021, 14, 157.	1.3	1
6	Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation. Journal of Steroid Biochemistry and Molecular Biology, 2020, 196, 105498.	1.2	10
7	The predicted collagen-binding domains of Drosophila SPARC are essential for survival and for collagen IV distribution and assembly into basement membranes. Developmental Biology, 2020, 461, 197-209.	0.9	5
8	Ventricular Zone Expressed PH Domain Containing 1 (VEPH1): an adaptor protein capable of modulating multiple signaling transduction pathways during normal and pathological development. Cell Communication and Signaling, 2019, 17, 116.	2.7	10
9	Removing Short Wavelengths From Polychromatic White Light Attenuates Circadian Phase Resetting in Rats. Frontiers in Neuroscience, 2019, 13, 954.	1.4	7
10	The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer. Hormones and Cancer, 2018, 9, 95-107.	4.9	6
11	Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model. Journal of Ovarian Research, 2018, 11, 56.	1.3	8
12	BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFÎºB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells. Neoplasia, 2018, 20, 697-709.	2.3	8
13	Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. International Journal of Gynecology and Obstetrics, 2018, 143, 325-332.	1.0	11
14	VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation. British Journal of Cancer, 2017, 116, 1065-1076.	2.9	26
15	Collagen IV trafficking: The inside-out and beyond story. Developmental Biology, 2017, 431, 124-133.	0.9	54
16	In vitro Autoradiographic Analysis of Regional Changes in Estrogen Receptor Alpha in the Brains of Cycling Female Rats. Neuroendocrinology, 2016, 103, 538-551.	1.2	1
17	Human ortholog of Drosophila Melted impedes SMAD2 release from TGF-Î² receptor I to inhibit TGF-Î² signaling. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3000-9.	3.3	20
18	Slow binding kinetics of secreted protein, acidic, rich in cysteine-VEGF interaction limit VEGF activation of VEGF receptor 2 and attenuate angiogenesis. FASEB Journal, 2015, 29, 3493-3505.	0.2	14

#	Article	IF	Citations
19	Glucocorticoid-Induced Reversal of Interleukin-1Î²-Stimulated Inflammatory Gene Expression in Human Oviductal Cells. PLoS ONE, 2014, 9, e97997.	1.1	9
20	Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites. BioMed Research International, 2014, 2014, 1-9.	0.9	27
21	C-terminal region of teneurin-1 co-localizes with the dystroglycan complex in adult mouse testes and regulates testicular size and testosterone production. Histochemistry and Cell Biology, 2014, 141, 191-211.	0.8	21
22	Altered expression of inflammation-associated genes in oviductal cells following follicular fluid exposure: Implications for ovarian carcinogenesis. Experimental Biology and Medicine, 2014, 239, 24-32.	1.1	38
23	Response to editorial entitled â€œBiomarkers of endometrial receptivity through a minimally invasive approachâ€• Fertility and Sterility, 2013, 100, e11.	0.5	3
24	Discovery of biomarkers of endometrial receptivity through a minimally invasive approach: a validation study with implications for assisted reproduction. Fertility and Sterility, 2013, 100, 810-817.e8.	0.5	36
25	GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoEâ^'/â^' Mice. Endocrinology, 2013, 154, 127-139.	1.4	288
26	C-terminal processing of the teneurin proteins: Independent actions of a teneurin C-terminal associated peptide in hippocampal cells. Molecular and Cellular Neurosciences, 2013, 52, 38-50.	1.0	33
27	Effects of Filtering Visual Short Wavelengths During Nocturnal Shiftwork on Sleep and Performance. Chronobiology International, 2013, 30, 951-962.	0.9	49
28	Evolution and Function of SPARC and Tenascins: Matricellular Counter-Adhesive Glycoproteins with Pleiotropic Effects on Angiogenesis and Tissue Fibrosis. Biology of Extracellular Matrix, 2013, , 191-220.	0.3	2
29	Prolonged Postovulatory Proinflammatory Signaling in the Fallopian Tube Epithelium May Be Mediated through a BRCA1/DAB2 Axis. Clinical Cancer Research, 2012, 18, 4334-4344.	3.2	20
30	The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer1This article is part of Special Issue entitled Asilomar Chromatin and has undergone the Journalâ€™s usual peer review process.. Biochemistry and Cell Biology, 2012, 90, 96-107.	0.9	3
31	Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity. Cellular and Molecular Life Sciences, 2012, 69, 3895-3909.	2.4	30
32	Cellâ€“cell and cellâ€“matrix dynamics in intraperitoneal cancer metastasis. Cancer and Metastasis Reviews, 2012, 31, 397-414.	2.7	121
33	Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. Journal of Clinical Investigation, 2012, 122, 388-402.	3.9	141
34	Dynamic Distribution of Nuclear Coactivator 4 during Mitosis: Association with Mitotic Apparatus and Midbodies. PLoS ONE, 2011, 6, e22257.	1.1	3
35	Knockdown of SPARC leads to decreased cellâ€“cell adhesion and lens cataracts during post-gastrula development in Xenopus laevis. Development Genes and Evolution, 2011, 220, 315-327.	0.4	8
36	Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma. Endocrine-Related Cancer, 2011, 18, 221-34.	1.6	14

#	Article	IF	Citations
37	Spectral modulation attenuates molecular, endocrine, and neurobehavioral disruption induced by nocturnal light exposure. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E518-E527.	1.8	51
38	Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecologic Oncology, 2010, 117, 9-17.	0.6	61
39	Variable Expression of Nuclear Receptor Coactivator 4 (NcoA4) During Mouse Embryonic Development. Journal of Histochemistry and Cytochemistry, 2010, 58, 595-609.	1.3	20
40	Maintaining Mesenchymal Properties of Ovarian Surface Epithelial Cells: A Potential Early Protective Role for TGF-Î² in Ovarian Carcinogenesis. Endocrinology, 2010, 151, 5092-5094.	1.4	3
41	Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 51-58.	1.2	25
42	Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 368-371.	1.2	44
43	Polymorphic Variation of Genes in the Fibrinolytic System and the Risk of Ovarian Cancer. PLoS ONE, 2009, 4, e5918.	1.1	9
44	Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. International Journal of Cancer, 2009, 124, 2060-2070.	2.3	212
45	Human embryonic stem cells secrete soluble factors that inhibit cancer cell growth. Cell Proliferation, 2009, 42, 788-798.	2.4	40
46	Modulation of aryl hydrocarbon receptor activity by four and a half LIM domain 2. International Journal of Biochemistry and Cell Biology, 2009, 41, 1182-1188.	1.2	10
47	Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration. BMC Cancer, 2008, 8, 223.	1.1	98
48	A Proteome Resource of Ovarian Cancer Ascites: Integrated Proteomic and Bioinformatic Analyses To Identify Putative Biomarkers. Journal of Proteome Research, 2008, 7, 339-351.	1.8	134
49	Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT). Molecular BioSystems, 2008, 4, 762.	2.9	47
50	Selectively Filtering Short Wavelengths Attenuates the Disruptive Effects of Nocturnal Light on Endocrine and Molecular Circadian Phase Markers in Rats. Endocrinology, 2008, 149, 6125-6135.	1.4	38
51	Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma. Clinical Cancer Research, 2008, 14, 4067-4078.	3.2	129
52	MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. British Journal of Cancer, 2007, 97, 358-367.	2.9	62
53	Transcriptional Activity of Androgen Receptor Is Modulated by Two RNA Splicing Factors, PSF and p54nrb. Molecular and Cellular Biology, 2007, 27, 4863-4875.	1.1	91
54	Phagocytosis of collagen by fibroblasts and invasive cancer cells is mediated by MT1-MMP. Biochemical Society Transactions, 2007, 35, 704-706.	1.6	34

#	Article	IF	Citations
55	Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene, 2007, 26, 198-214.	2.6	36
56	Functional interaction of nuclear receptor coactivator 4 with aryl hydrocarbon receptor. Biochemical and Biophysical Research Communications, 2006, 346, 526-534.	1.0	40
57	A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis. Diabetes, 2004, 53, 2492-2500.	0.3	318
58	Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology, 2004, 127, 546-558.	0.6	320
59	Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 493-502.	1.2	15
60	Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells. Cancer Research, 2003, 63, 2416-24.	0.4	19
61	Interaction with Nedd8, a Ubiquitin-like Protein, Enhances the Transcriptional Activity of the Aryl Hydrocarbon Receptor. Journal of Biological Chemistry, 2002, 277, 44028-44034.	1.6	22
62	Androgen Modulation of Adhesion and Antiadhesion Molecules in PC-3 Prostate Cancer Cells Expressing Androgen Receptor. Endocrinology, 2002, 143, 3897-3904.	1.4	37
63	Novel Functions of the Matricellular Proteins Osteopontin and Osteonectin/SPARC. Connective Tissue Research, 2002, 43, 308-319.	1.1	73
64	Flavonoids can block PSA production by breast and prostate cancer cell lines. Clinica Chimica Acta, 2002, 317, 17-26.	0.5	47
65	Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. International Journal of Cancer, 2002, 100, 507-514.	2.3	43
66	Novel Functions of the Matricellular Proteins Osteopontin and Osteonectin/SPARC. Connective Tissue Research, 2002, 43, 308-319.	1.1	19
67	Activation of Androgen Receptor-Associated Protein 70 (ARA70) mRNA Expression in Ovarian Cancer. Gynecologic Oncology, 2001, 80, 132-138.	0.6	32
68	Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Research and Treatment, 2001, 67, 245-253.	1.1	40
69	Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling. Journal of Biological Chemistry, 2001, 276, 21489-21499.	1.6	98
70	Activation of SPARC Expression in Reactive Stroma Associated with Human Epithelial Ovarian Cancer. Gynecologic Oncology, 1999, 75, 25-33.	0.6	66
71	Hormonal Interactions in the Effects of Halogenated Aromatic Hydrocarbons On the Developing Brain. Toxicology and Industrial Health, 1998, 14, 185-208.	0.6	29
72	Regulation of Gonadotropin-Releasing Hormone (GnRH) Gene Expression by 5Î±-Dihydrotestosterone in GnRH-Secreting GT1â€“7 Hypothalamic Neurons¹. Endocrinology, 1998, 139, 1108-1114.	1.4	70

#	Article	IF	Citations
73	Regulation of Gonadotropin-Releasing Hormone (GnRH) Gene Expression by 5Â-Dihydrotestosterone in GnRH-Secreting GT1-7 Hypothalamic Neurons. Endocrinology, 1998, 139, 1108-1114.	1.4	21
74	Leptin Sensitivity in Nonobese Glucagon-Like Peptide I Receptor â^'/â^' Mice. Diabetes, 1997, 46, 2029-2034.	0.3	18
75	Corticotropin-Releasing Factor, But Not Corticosterone, Is Involved in Stress-Induced Relapse to Heroin-Seeking in Rats. Journal of Neuroscience, 1997, 17, 2605-2614.	1.7	293
76	Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Molecular and Cellular Endocrinology, 1997, 126, 59-73.	1.6	152
77	Sex and the developing brain: suppression of neuronal estrogen sensitivity by developmental androgen exposure. Neurochemical Research, 1997, 22, 1395-1414.	1.6	48
78	Leptin sensitivity in nonobese glucagon-like peptide I receptor -/- mice. Diabetes, 1997, 46, 2029-2034.	0.3	8
79	Rationale for Estrogen With Interrupted Progestin as a New Low-Dose Hormonal Replacement Therapy. Journal of the Society for Gynecologic Investigation, 1996, 3, 225-234.	1.9	2
80	Regulation of Estrogen Receptor Concentrations in the Rat Brain: Effects of Sustained Androgen and Estrogen Exposure. Neuroendocrinology, 1996, 63, 53-60.	1.2	87
81	Sex differences in corticosteroid binding in the rat brain: an in vitro autoradiographic study. Brain Research, 1996, 708, 71-81.	1.1	28
82	Sex differences in estrogen receptor and progestin receptor induction in the guinea pig hypothalamus and preoptic area. Brain Research, 1996, 725, 37-48.	1.1	25
83	Glucose intolerance but normal satiety in mice with a null mutation in the glucagonâ€"like peptide 1 receptor gene. Nature Medicine, 1996, 2, 1254-1258.	15.2	710
84	Rationale for estrogen with interrupted progestin as a new low-dose hormonal replacement therapy. Journal of the Society for Gynecologic Investigation, 1996, 3, 225-234.	1.9	6
85	Sexual differentiation of estrogen receptor concentrations in the rat brain: effects of neonatal testosterone exposure. Brain Research, 1995, 691, 229-234.	1.1	52
86	Localization and measurement of occupied androgen receptors in thaw-mounted rat and human prostate tissue sections by in vitro autoradiography. Steroids, 1995, 60, 239-247.	0.8	5
87	In vitro labeling of gonadal steroid hormone receptors in brain tissue sections. Steroids, 1995, 60, 726-737.	0.8	33
88	Immunocytochemical detection of androgen receptor in human temporal cortex: Characterization and application of polyclonal androgen receptor antibodies in frozen and paraffin-embedded tissues. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 197-209.	1.2	101
89	Partial Demasculinization and Feminization of Sex Behavior in Male Rats by in Utero and Lactational Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin Is Not Associated with Alterations in Estrogen Receptor Binding or Volumes of Sexually Differentiated Brain. Toxicology and Applied Pharmacology, 1994, 127, 258-267.	1.3	99
90	Androgen Treatment Decreases Estrogen Receptor Binding in the Ventromedial Nucleus of the Rat Brain: A Quantitative in Vitro Autoradiographic Analysis. Molecular and Cellular Neurosciences, 1994, 5, 549-555.	1.0	34

#	Article	IF	Citations
91	Sex Differences in the Development of Estrogen Receptors in the Rat Brain. Hormones and Behavior, 1994, 28, 483-491.	1.0	96
92	Synthesis and Evaluation of 7.alpha.-Iodo-5.alpha.-dihydrotestosterone as a Potential Radioligand for Androgen Receptor. Journal of Medicinal Chemistry, 1994, 37, 1224-1230.	2.9	18
93	Progesterone Modulation of Estrogen Receptors in Microdissected Regions of the Rat Hypothalamus. Molecular and Cellular Neurosciences, 1994, 5, 283-290.	1.0	36
94	Pubertal Development of Estrogen Receptors in the Rat Brain. Molecular and Cellular Neurosciences, 1994, 5, 475-483.	1.0	13
95	In Vitro Autoradiography for Steroid Receptors. Methods in Neurosciences, 1994, , 116-142.	0.5	0
96	7Î±-Methyl-17Î±-(E-2'-[125I]iodovinyl)-19-nortestosterone: a new radioligand for the detection of androgen receptor. Steroids, 1993, 58, 13-23.	0.8	16
97	In vitro autoradiographic visualization of occupied estrogen receptors in the rat brain with an iodinated estrogen ligand.. Journal of Histochemistry and Cytochemistry, 1993, 41, 1279-1290.	1.3	13
98	Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4668-4672.	3.3	429
99	Sex differences in estrogen receptor binding in the rat hypothalamus: effects of subsaturating pulses of estradiol. Brain Research, 1992, 578, 129-134.	1.1	29
100	Transmitter Content and Afferent Connections of Estrogen-Sensitive Progestin Receptor-Containing Neurons in the Primate Hypothalamus. Neuroendocrinology, 1992, 55, 667-682.	1.2	75
101	Estrogen receptor binding in regions of the rat hypothalamus and preoptic area after inhibition of dopamine-Î²-hydroxylase. Brain Research, 1991, 549, 260-267.	1.1	6
102	Comparison of Age- and Sex-Related Changes in Cell Nuclear Estrogen-Binding Capacity and Progestin Receptor Induction in the Rat Brain*. Endocrinology, 1990, 126, 2965-2972.	1.4	103
103	Progestin receptor-containing cells in guinea pig hypothalamus: Afferent connections, morphological characteristics, and neurotransmitter content. Molecular and Cellular Neurosciences, 1990, 1, 58-77.	1.0	52
104	Prazosin treatment does not affect progestin receptor induction in microdissected regions of the rat hypothalamus. Brain Research, 1990, 512, 238-242.	1.1	2
105	Dilute Estradiol Implants and Progestin Receptor Induction in the Ventromedial Nucleus of the Hypothalamus: Correlation with Receptive Behavior in Female Rats*. Endocrinology, 1989, 124, 1807-1812.	1.4	62
106	Characterization of 11Î²-Methoxy-16Î±-[125I]Iodoestradiol Binding: Neuronal Localization of Estrogen-Binding Sites in the Developing Rat Brain*. Endocrinology, 1989, 124, 2074-2088.	1.4	37
107	Regional Sex Differences in Cell Nuclear Estrogen-Binding Capacity in the Rat Hypothalamus and Preoptic Area*. Endocrinology, 1988, 123, 1761-1770.	1.4	92
108	Maintenance of Progesterone-Facilitated Sexual Behavior in Female Rats Requires Continued Hypothalamic Protein Synthesis and Nuclear Progestin Receptor Occupation*. Endocrinology, 1987, 121, 298-304.	1.4	49

#	Article	IF	Citations
109	Hypothalamic nuclear progestin receptors and the duration of sexual receptivity in ovariectomized and ovariectomized-hysterectomized rats. Physiology and Behavior, 1986, 36, 211-215.	1.0	8
110	Abbreviation of the period of sexual behavior in female guinea pigs by the progesterone antagonist RU 486. Brain Research, 1986, 373, 103-113.	1.1	30
111	Some Catecholamine Inhibitors Do Not Cause Accumulation of Nuclear Estrogen Receptors in Rat Hypothalamus and Anterior Pituitary Gland. Neuroendocrinology, 1986, 43, 143-149.	1.2	24
112	Dopamine-Î²-hydroxylase Inhibitors Modulate the Concentration of Functional Estrogen Receptors in Female Rat Hypothalamus and Pituitary Gland. Neuroendocrinology, 1986, 43, 150-158.	1.2	40
113	Loss of hypothalamic nuclear-bound progestin receptors: Factors involved and the relationship to heat termination in female guinea pigs. Brain Research, 1985, 358, 180-190.	1.1	23
114	Supplemental Progesterone Delays Heat Termination and the Loss of Progestin Receptors from Hypothalamic Cell Nuclei in Female Guinea Pigs. Neuroendocrinology, 1984, 39, 384-391.	1.2	21
115	1-(o-Chlorophenyl)-1(p-Chlorophenyl)2,2,2-Trichloroethane Induces Functional Progestin Receptors in the Rat Hypothalamus and Pituitary Gland*. Endocrinology, 1984, 115, 2052-2058.	1.4	10
116	Progesterone decrease the concentration of hypothalamic and anterior pituitary estrogen receptors in ovariectomized rats. Brain Research, 1984, 304, 225-236.	1.1	47
117	Inhibition of sexual behavior in female guinea pigs by a progestin receptor antagonist. Brain Research, 1984, 301, 343-349.	1.1	96
118	Failure of protein synthesis inhibition to block progesterone desensitization of lordosis in female rats. Physiology and Behavior, 1982, 29, 475-481.	1.0	24